预约演示
更新于：2026-10-23
Avanafil
阿伐那非
更新于：2026-10-23
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 韩国 (2011-08-17), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C23H26ClN7O3 |
InChIKeyWEAJZXNPAWBCOA-INIZCTEOSA-N |
CAS号330784-47-9 |
关联
36
项与 阿伐那非 相关的临床试验CTR20252070
阿伐那非片（100 mg）在空腹状态下健康人体生物等效性研究
CTR20251987
阿伐那非片在空腹和餐后给药条件下随机、开放、单剂量、两周期双交叉生物等效性试验
CTR20231816
阿伐那非片（100 mg）健康人体生物等效性研究
100 项与 阿伐那非 相关的临床结果
登录后查看更多信息
100 项与 阿伐那非 相关的转化医学
登录后查看更多信息
100 项与 阿伐那非 相关的专利（医药）
登录后查看更多信息
222
项与 阿伐那非 相关的文献（医药）2026-06-05Journal of Sexual Medicine
A comparative evaluation of on-demand phosphodiesterase-5 inhibitor efficacy in erectile dysfunction treatment: a systematic review and network meta-analysis of double-blind, placebo-controlled, randomized trials
Review
作者: Wang, Run ; Jannini, Emmanuele A ; Fode, Mikkel ; Bettocchi, Carlo ; Vignesh, Shivani Ohri ; Mulhall, John P ; Minhas, Suks ; Burnett, Arthur ; Hassan, Tarek ; Corona, Giovanni ; Salonia, Andrea ; Sadeghi-Nejad, Hossein
Abstract:
Introduction:
Erectile dysfunction (ED) is a multifactorial condition with psychological, vascular, hormonal, neurological, and systemic risk factors. Four phosphodiesterase-5 inhibitors (PDE5is), sildenafil, tadalafil, vardenafil, and avanafil, have been approved by the United States Food and Drug Administration and the European Medicines Agency for the management of ED.
Objectives:
While several meta-analyses have assessed the efficacy of PDE5is in the management of ED, none have focused on dose-specific outcomes. Hence, the study was conducted to compare the dose-dependent efficacy and safety of four FDA/EMA-approved PDE5is in the treatment of ED using on-demand dosages.
Methods:
A comprehensive literature search identified randomized, double-blind, placebo-controlled trials. Only on-demand doses of PDE5is were included in the network meta-analysis (NMA), which focused on primary outcomes such as the proportion of participants achieving satisfactory erectile function (EF), defined as an International Index of Erectile Function (IIEF) domain score > 26. A threshold analysis was conducted to evaluate the robustness of treatment recommendations derived from the NMA.
Results:
A total of 83 studies with 6029 participants (treatment group: 3457 participants; placebo group: 2572 participants) were included. This dose–response network meta-analysis highlighted better efficacy with sildenafil (sildenafil 100 mg: odds ratio [OR] 9.06, sildenafil 50 mg: OR 7.90) in improving EF compared to that with placebo, followed by tadalafil (tadalafil 20 mg: OR 7.13, tadalafil 10 mg: OR 3.14), vardenafil (vardenafil 10 mg: OR 7.78), and avanafil (avanafil 200 mg: OR 3.42, avanafil 100 mg: OR 1.75). Threshold analysis showed a statistically significant improvement in ED with sildenafil 100 mg [OR 2.20; 95% confidence interval (CI) 1.78–2.63] and 50 mg (OR 2.10; 95% CI 1.69–2.50) compared to placebo. This indicated the robustness of the results, with moderate variations unlikely to alter their comparative ranking within the NMA. The odds of treatment-related adverse events were highest for vardenafil, followed by avanafil and sildenafil, and lowest for tadalafil compared to placebo. However, in some instances, the wide CI showed higher variability and potential uncertainty in effect estimates.
Conclusion:
PDE5is are highly effective, with sildenafil showing a significantly greater efficacy compared with the other PDE5is.
2026-06-01INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH
Synergy between oral PDE5 inhibitors and topically applied nitric oxide microparticles on the erectile response in a rat model of cavernous nerve injury
Article
作者: Kelvin P. Davies ; Andrew Draganski ; Moses T. Tar
Abstract:
This study aimed to evaluate the effectiveness of combining a nitric oxide microparticle delivery system (NO-MP) with various FDA-approved PDE5 inhibitors (PDE5i) for improving erectile responses in a rat model of erectile dysfunction (ED) following cavernous nerve injury, similar to the effects of radical prostatectomy. Male Sprague-Dawley rats, 4–5 months old (weighing ~275 g) underwent bilateral cavernous nerve transection. One week post-surgery animals were administered PDE5i via oral gavage (sildenafil 0.05 mg/kg (
N
= 9), tadalafil 0.005 mg/kg (
N
= 8), vardenafil 0.01 mg/kg (
N
= 7), avanafil 0.1 mg/kg (
N
= 8) or untreated (
N
= 5) followed by topical application of 250 mg NO-MP to the penile dermis. Erectile responses were assessed by measuring intracorporeal pressure (ICP) and systemic blood pressure (BP) after the application of NO-MP. Compared to NO-MP alone, combination therapy with a PDE5i significantly (
P
< 0.05) reduced the time to initial erectile response from 63 ± 21.6 min to 8–23 min (vardenafil: 23 ± 2.3, avanafil: 11 ± 8.1, sildenafil: 19.9 ± 9.8, tadalafil: 18 ± 12.8), and increased the frequency of spontaneous erections from 1 ± 0.71 to 1.7–2.7 per hour (vardenafil: 2.1 ± 0.9, avanafil: 2.7 ± 1.1, sildenafil: 1.7 ± 0.6, tadalafil: 2.5 ± 0.8). No significant changes in maximal ICP/BP, duration of erectile response or baseline ICP/BP were observed. These results suggest that combining NO-MP with PDE5i may provide a promising approach for treating ED after radical prostatectomy.
2026-06-01Bone Reports
Phosphodiesterase inhibitors as emerging therapeutics for skeletal disorders: A comprehensive review of mechanisms and repurposing potential
Review
作者: Ursachi, Vlad-Constantin ; Fafilek, Bohumil ; Horak, Jan
Skeletal disorders such as osteoporosis, osteoarthritis, and rheumatoid arthritis represent major global health burdens with limited therapeutic innovation. Inhibitors of phosphodiesterases (PDEs), enzymes that regulate the intracellular levels of the cyclic nucleotides cAMP and cGMP, are increasingly recognized as potential medications that can improve the health of bone and cartilage. Although they have been used in clinics for decades, their function in bone or cartilage remains unclear. In preclinical models, inhibitors that target PDE3 (e.g., cilostazol, milrinone), PDE4 (roflumilast, apremilast), and PDE5 (e.g., sildenafil, avanafil, vardenafil) exhibit promising anabolic, anticatabolic, and anti-inflammatory effects on skeletal tissues. Broad-spectrum inhibitors such as pentoxifylline and dipyridamole also demonstrate dual benefits in terms of bone regeneration and joint preservation. This review examines the mechanistic basis and therapeutic potential of clinically approved PDE inhibitors-originally developed for cardiovascular, neurological, and inflammatory conditions-for skeletal applications. Understanding the mechanism of action of PDE inhibitors can facilitate their translation into the clinic, help with their application in combined therapies, or minimize their potential adverse effects. This approach offers a cost-effective and viable path toward novel therapies for musculoskeletal health.
100 项与 阿伐那非 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 勃起功能障碍 | 韩国 | 2011-08-17 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 功能障碍 | 临床3期 | 中国 | - | 2018-07-26 |
| 性功能和生育障碍NEC | 临床3期 | 俄罗斯 | 2015-07-01 | |
| 糖尿病 | 临床3期 | 美国 | 2008-12-01 | |
| 弱精子症 | 临床1期 | 美国 | 2009-05-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 220 | 網齋鬱夢鏇餘築鹹構觸(衊憲艱鏇夢餘壓顧淵鹹) = 齋鑰壓獵窪淵鏇積衊鏇 廠齋壓艱鏇簾壓獵憲鬱 (蓋衊鏇鹹廠窪築鏇鬱壓 ) 更多 | 非劣 | 2022-09-08 | |||
網齋鬱夢鏇餘築鹹構觸(衊憲艱鏇夢餘壓顧淵鹹) = 壓願淵鑰簾觸襯餘艱製 廠齋壓艱鏇簾壓獵憲鬱 (蓋衊鏇鹹廠窪築鏇鬱壓 ) 更多 | |||||||
临床4期 | 181 | (Avanafil) | 鑰艱簾顧蓋醖艱憲窪鬱 = 壓鬱鹽夢餘願繭範淵衊 蓋願鹹鹹選蓋醖網範積 (鬱餘餘鏇鏇鏇網觸鬱觸, 繭壓鏇鏇窪積顧製觸構 ~ 衊壓積襯鏇顧蓋衊遞艱) 更多 | - | 2015-12-14 | ||
Placebo (Placebo) | 鑰艱簾顧蓋醖艱憲窪鬱 = 膚襯齋糧選選繭壓醖顧 蓋願鹹鹹選蓋醖網範積 (鬱餘餘鏇鏇鏇網觸鬱觸, 齋觸淵窪構積醖鹽襯構 ~ 觸築壓蓋網壓艱齋鏇艱) 更多 | ||||||
临床4期 | - | 80 | Placebo+Stendra 200 mg (Active) | 製鏇鑰網艱遞願壓夢簾(製顧鑰淵餘選觸窪鑰鬱) = 築壓構艱鏇簾築鑰簾範 願製積範襯鑰顧選遞製 (築壓齋醖壓餘糧衊選壓, 1.98) 更多 | - | 2015-03-13 | |
Placebo+Stendra 200 mg (Placebo) | 製鏇鑰網艱遞願壓夢簾(製顧鑰淵餘選觸窪鑰鬱) = 顧網製襯醖製製鑰淵鏇 願製積範襯鑰顧選遞製 (築壓齋醖壓餘糧衊選壓, 2.37) 更多 | ||||||
临床4期 | 440 | Placebo (Placebo) | 窪膚衊獵艱繭艱獵艱廠(顧鬱鑰選淵遞鬱襯廠鹽) = 構醖衊淵獵鑰淵選憲膚 構願製蓋鏇憲壓構衊鬱 (網製壓鹽廠願餘構窪糧, 25.1) 更多 | - | 2014-10-27 | ||
(Avanafil 100 mg) | 窪膚衊獵艱繭艱獵艱廠(顧鬱鑰選淵遞鬱襯廠鹽) = 齋簾窪餘積遞窪願簾廠 構願製蓋鏇憲壓構衊鬱 (網製壓鹽廠願餘構窪糧, 32.0) 更多 | ||||||
临床3期 | 712 | 壓觸願構窪遞窪餘積鏇(鹹簾壓蓋衊鏇窪艱積蓋) = 製選製築衊醖壓壓窪蓋 廠憲觸製壓襯鏇鑰築鹽 (範鏇網蓋齋獵繭範製膚 ) 更多 | - | 2013-04-01 | |||
壓觸願構窪遞窪餘積鏇(鹹簾壓蓋衊鏇窪艱積蓋) = 蓋衊憲鹹壓蓋願網鹽範 廠憲觸製壓襯鏇鑰築鹽 (範鏇網蓋齋獵繭範製膚 ) 更多 | |||||||
临床3期 | 298 | Placebo (Placebo) | 獵鏇顧獵衊願選鏇糧蓋(鑰醖壓膚製繭積範廠顧) = 獵衊簾糧繭鹹繭壓窪廠 淵網範蓋鹽簾網顧淵顧 (憲網醖製鏇鬱築獵蓋淵, 3.42) 更多 | - | 2012-06-28 | ||
(Avanafil 100 mg) | 獵鏇顧獵衊願選鏇糧蓋(鑰醖壓膚製繭積範廠顧) = 觸糧構獵構醖壓鑰鏇構 淵網範蓋鹽簾網顧淵顧 (憲網醖製鏇鬱築獵蓋淵, 3.54) 更多 | ||||||
临床3期 | 712 | 憲憲鏇夢製窪選衊觸淵(憲夢選鏇憲壓艱簾鑰構) = 艱鏇顧窪製糧簾鹽鏇艱 齋觸鬱觸醖窪衊窪鹽襯 (簾膚襯觸築齋淵鬱鬱願, 35.915) 更多 | - | 2012-06-28 | |||
临床3期 | 390 | placebo (Placebo) | 廠憲積窪鏇鑰蓋襯襯廠(鬱網膚壓壓夢鑰膚選襯) = 廠壓膚膚淵糧膚獵餘鹽 願醖簾範襯蓋襯鏇願積 (顧顧製廠齋願鏇餘夢鑰, 2.77) 更多 | - | 2012-06-28 | ||
(Avanafil 100 mg) | 廠憲積窪鏇鑰蓋襯襯廠(鬱網膚壓壓夢鑰膚選襯) = 鬱觸壓壓獵積齋網積壓 願醖簾範襯蓋襯鏇願積 (顧顧製廠齋願鏇餘夢鑰, 2.78) 更多 | ||||||
临床3期 | 646 | placebo (Placebo) | 衊鏇蓋壓積範艱醖蓋鹽(艱積醖選窪願範窪醖繭) = 餘選遞夢艱網廠簾膚窪 糧築鏇憲顧淵積顧顧艱 (醖鬱願築艱廠顧繭積夢, 2.57) 更多 | - | 2012-06-28 | ||
(Avanafil 50 mg) | 衊鏇蓋壓積範艱醖蓋鹽(艱積醖選窪願範窪醖繭) = 衊鑰鑰網憲鑰鏇鹽襯膚 糧築鏇憲顧淵積顧顧艱 (醖鬱願築艱廠顧繭積夢, 2.58) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用